Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new study led by Professor Seena Fazel at the University of Oxford found that among patients with chronic, non-communicable diseases, the risk of death is more than doubled if they also have a psychiatric disease.

Stethoscope and keyboard

The study, published in PLOS Medicine, included national registers in Sweden to investigate more than one million patients who had diagnoses of chronic respiratory disease, cardiovascular disease, and diabetes. More than a quarter (25-32%) of people in the analysis had a co-occurring lifetime diagnosis of any psychiatric disorder.

Non-communicable diseases, such as diabetes and heart disease are a global public health challenge accounting for an estimated 40 million excess deaths annually.

Professor Seena Fazel, Department of Psychiatry, University of Oxford, said:

 

'This adds to the emerging evidence that improving assessment, treatment, and follow-up of people with comorbid psychiatric disorders will reduce mortality and suicide risk in people with chronic non-communicable diseases.'

Within five years of diagnosis, at least 7% of the people included in the study had died from any cause and 0.3% had died from suicide. Comorbid (two or more diseases in a patient) psychiatric disorders were associated with higher all-cause mortality (15.4%-21.1% over five years) when compared to those without such conditions (5.5%-9.1%).

When the researchers compared each patient with an unaffected sibling, who did not have the chronic health condition, so as to account for risk factors shared within families, such as early environment and genes, psychiatric comorbidity remained consistently associated with elevated rates of premature mortality and suicide. Risks ranged by psychiatric diagnosis; for instance, mortality risks were elevated by up to nine times in those with comorbid substance use disorder compared to unaffected siblings, and by up to seven times in those with comorbid depression.

One study limitation is that the use of population-based registries to identify patients meant that psychiatric comorbidities were diagnosed in outpatient and hospital settings and those with less severe psychiatric disorders could be missed.

Overall the findings point towards better integration of services for chronic physical, mental health and substance use services, and underscore the importance or primary care in the early diagnosis and treatment of psychiatric disorders.

NIHR OXFORD HEALTH BIOMEDICAL RESEARCH CENTRE NEWS

Please follow the link below to read the news on the NIHR BRC website.

Similar stories

Treating mental illness with electricity - new podcast

A new wave of treatments that stimulate the brain with electricity are showing promise on patients and in clinical trials.

Hours of gaming not negatively impacting wellbeing of most adolescents - new study

University of Oxford researchers found that although many school-age adolescents are spending considerable time gaming, it is not having a negative impact on their wellbeing.

Few mental health apps make it to real world, according to new Oxford University study

Despite enthusiasm for digital technology in addressing young people’s mental health, few effective apps have been successfully rolled out.

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients.

Dementia research - new trial with diabetes drug

An important new trial will test the effects of oral semaglutide on the build-up of a protein in the brain that characterises Alzheimer's disease.